相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture
Daniel Sepulveda-Crespo et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection
C. A. M. Stedman et al.
HAEMOPHILIA (2016)
Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection
Maria Ripoli et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2016)
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
Stefan Zeuzem et al.
JOURNAL OF HEPATOLOGY (2016)
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial
Stefan Zeuzem et al.
ANNALS OF INTERNAL MEDICINE (2015)
Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics
Jinjin Zhang et al.
BIOMATERIALS (2015)
Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
Gregory J. Dore et al.
GASTROENTEROLOGY (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference
Josune Torrecilla et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2015)
A PHASE 3, RANDOMISED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 8 AND 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITHOUT CIRRHOSIS: OPTIMIST-1
P. Kwo et al.
JOURNAL OF HEPATOLOGY (2015)
Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro
Xiaofeng Hang et al.
JOURNAL OF VIROLOGICAL METHODS (2015)
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
Christophe Hezode et al.
LANCET (2015)
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
Anita Kohli et al.
LANCET INFECTIOUS DISEASES (2015)
A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells
Abirami Lakshminarayanan et al.
NANOSCALE (2015)
Avoiding treatment failures associated with HCV resistance
Jean-Michel Pawlotsky
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
J. J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Recent advances and future directions in the management of hepatitis C infections
Victoria Belousova et al.
PHARMACOLOGY & THERAPEUTICS (2015)
MODELING THE COST-EFFECTIVENESS OF THE ALL ORAL, DIRECT-ACTING ANTIVIRAL REGIMEN DACLATASVIR PLUS SOFOSBUVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HIV
P. McEwan et al.
VALUE IN HEALTH (2015)
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection
Marc Bourliere et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
Aptamer-conjugated magnetic nanoparticles for the efficient removal of HCV particles from human plasma samples
Najmeh Delaviz et al.
RSC ADVANCES (2015)
Development of microRNA therapeutics is coming of age
Eva van Rooij et al.
EMBO MOLECULAR MEDICINE (2014)
SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY
R. Esteban et al.
JOURNAL OF HEPATOLOGY (2014)
Development of Biodegradable Nanoparticles for Liver-Specific Ribavirin Delivery
Tsutomu Ishihara et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Phosphorylation of Hepatitis C Virus RNA Polymerases Ser29 and Ser42 by Protein Kinase C-Related Kinase 2 Regulates Viral RNA Replication
Song-Hee Han et al.
JOURNAL OF VIROLOGY (2014)
Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection
Jinjin Zhang et al.
BIOMATERIALS (2013)
P19: Ribavirin-boronic acid loaded nanoparticles: a possible route to improve hepatitis C treatment
Y Abo-zeid et al.
JOURNAL OF VIRAL HEPATITIS (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
Stefanie A. Mortimer et al.
NUCLEIC ACIDS RESEARCH (2013)
Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown
Soo-Ryoon Ryoo et al.
BIOMATERIALS (2012)
Anti-Hepatitis C Virus Drugs in Development
Esperance A. K. Schaefer et al.
GASTROENTEROLOGY (2012)
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
Christoph Welsch et al.
GUT (2012)
Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naive Infected Individuals
Salvador Fonseca-Coronado et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex
Tetsuro Shimakami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Current status and future directions in the management of chronic hepatitis C
Wosen Aman et al.
VIROLOGY JOURNAL (2012)
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
Ann D. Kwong et al.
NATURE BIOTECHNOLOGY (2011)
Nanotechnology solutions for infectious diseases in developing nations Preface
Alejandro Sosnik et al.
ADVANCED DRUG DELIVERY REVIEWS (2010)
Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
Abdelhakim Ahmed-Belkacem et al.
GASTROENTEROLOGY (2010)
Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle
Jessica Wagoner et al.
HEPATOLOGY (2010)
Nanomedicine-Nanoscale Drugs and Delivery Systems
Surya Singh
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2010)
Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
Robert E. Lanford et al.
SCIENCE (2010)
Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus
Michael D. Bobardt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A virocidal arnphipathic α-helical peptide that inhibits hepatitis C virus infection in vitro
Guofeng Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain
Mohan Babu Appaiahgari et al.
MOLECULAR THERAPY (2007)
Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture
Ralf Bartenschlager et al.
VIRUS RESEARCH (2007)
Development and characterisation of chitosan nanoparticles for siRNA delivery
Haliza Katas et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques
Barbara M. Rothen-Rutishauser et al.
ENVIRONMENTAL SCIENCE & TECHNOLOGY (2006)
Global epidemiology of hepatitis C virus infection
CW Shepard et al.
LANCET INFECTIOUS DISEASES (2005)
Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes
XM Jiao et al.
JOURNAL OF GENERAL VIROLOGY (2004)
RNA interference: Biology, mechanism, and applications
N Agrawal et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2003)
Interference of hepatitis C virus RNA replication by short interfering RNAs
SB Kapadia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein
M Pallaoro et al.
JOURNAL OF VIROLOGY (2001)
Medical progress: Hepatitis C virus infection.
GM Lauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Replication of hepatitis C virus
R Bartenschlager et al.
JOURNAL OF GENERAL VIROLOGY (2000)
分享论文
